{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:29:38Z","timestamp":1791948578766,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["1H79TI026138"],"award-info":[{"award-number":["1H79TI026138"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jsat.2019.10.005","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T19:26:20Z","timestamp":1574105180000},"page":"80-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"special_numbering":"C","title":["Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine"],"prefix":"10.1016","volume":"109","author":[{"given":"Judith I.","family":"Tsui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Mayfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Speaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawir","family":"Yakup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Funai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Leroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph O.","family":"Merrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2019.10.005_bb0005","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","article-title":"Collaborative care of opioid-addicted patients in primary care using buprenorphine: Five-year experience","volume":"171","author":"Alford","year":"2011","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.jsat.2019.10.005_bb0010","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1080\/10826084.2016.1271432","article-title":"Heroin and methamphetamine injection: An emerging drug use pattern","volume":"52","author":"Al-Tayyib","year":"2017","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.jsat.2019.10.005_bb0015","series-title":"Methamphetamine: A regional drug crisis","author":"Artigiani","year":"2018"},{"key":"10.1016\/j.jsat.2019.10.005_bb0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13722-017-0072-2","article-title":"Public sector low threshold office-based buprenorphine treatment: Outcomes at year 7","volume":"12","author":"Bhatraju","year":"2017","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1016\/j.jsat.2019.10.005_bb0025","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/archgenpsychiatry.2011.124","article-title":"Mirtazapine to reduce methamphetamine use: A randomized controlled trial","volume":"68","author":"Colfax","year":"2011","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.jsat.2019.10.005_bb0030","first-page":"500","article-title":"Buprenorphine treatment in an urban community health center: What to expect","volume":"40","author":"Cunningham","year":"2008","journal-title":"Family Medicine"},{"key":"10.1016\/j.jsat.2019.10.005_bb0035","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1521-0391.2013.12032.x","article-title":"Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users","volume":"22","author":"Cunningham","year":"2013","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.jsat.2019.10.005_bb0040","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1360-0443.2005.01050.x","article-title":"Four-year follow-up of imprisoned male heroin users and methadone treatment: Mortality, re-incarceration and hepatitis C infection","volume":"100","author":"Dolan","year":"2005","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.10.005_bb0045","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1360-0443.2011.03771.x","article-title":"Topiramate for the treatment of methamphetamine addiction: A multi-center placebo-controlled trial","volume":"107","author":"Elkashef","year":"2012","journal-title":"Addiction"},{"issue":"Suppl. 1","key":"10.1016\/j.jsat.2019.10.005_bb0050","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/QAI.0b013e3182097537","article-title":"Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine\/naloxone","volume":"56","author":"Fiellin","year":"2011","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.jsat.2019.10.005_bb0055","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1176\/appi.ps.201300235","article-title":"Medication-assisted treatment with methadone: Assessing the evidence","volume":"65","author":"Fullerton","year":"2014","journal-title":"Psychiatric Services"},{"key":"10.1016\/j.jsat.2019.10.005_bb0060","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.drugalcdep.2017.10.011","article-title":"Increasing methamphetamine injection among non-MSM who inject drugs in King County, Washington","volume":"182","author":"Glick","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2019.10.005_bb0065","first-page":"Cd004145","article-title":"Substitution treatment of injecting opioid users for prevention of HIV infection","author":"Gowing","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2019.10.005_bb0070","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jsat.2013.10.004","article-title":"Leaving buprenorphine treatment: patients\u2019 reasons for cessation of care","volume":"46","author":"Gryczynski","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.10.005_bb0075","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.10.005_bb9235","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1176\/appi.ajp.2008.08020304","article-title":"Naltrexone for the treatment of amphetamine dependence: A randomized , placebo-controlled trial","volume":"165","author":"Jayaram-Lindstr\u00f6m","year":"2008","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.jsat.2019.10.005_bb0080","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jsat.2015.06.010","article-title":"Office-based opioid treatment with buprenorphine (OBOT-B): Statewide implementation of the Massachusetts Collaborative Care Model in community health centers","volume":"60","author":"LaBelle","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.10.005_bb0085","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jsat.2019.10.005_bb9240","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/add.12608","article-title":"Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder","volume":"109","author":"Ling","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.10.005_bb0090","doi-asserted-by":"crossref","first-page":"e5945","DOI":"10.1136\/bmj.e5945","article-title":"Opiate substitution treatment and HIV transmission in people who inject drugs: Systematic review and meta-analysis","volume":"345","author":"MacArthur","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jsat.2019.10.005_bb0095","first-page":"Cd002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2019.10.005_bb0100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/SAR.S138439","article-title":"A review of contingency management for the treatment of substance-use disorders: Adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies","volume":"9","author":"McPherson","year":"2018","journal-title":"Substance Abuse and Rehabilitation"},{"key":"10.1016\/j.jsat.2019.10.005_bb0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jsat.2015.05.005","article-title":"Buprenorphine treatment and 12-step meeting attendance: Conflicts, compatibilities, and patient outcomes","volume":"57","author":"Monico","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.10.005_bb0110","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.drugalcdep.2018.06.017","article-title":"HIV infection among MSM who inject methamphetamine in 8 US cities","volume":"190","author":"Nerlander","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2019.10.005_bb0115","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1111\/add.12682","article-title":"The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users","volume":"109","author":"Nolan","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.10.005_bb0120","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1360-0443.2009.02856.x","article-title":"The effect of time spent in treatment and dropout status on rates of convictions, cautions and imprisonment over 5 years in a primary care-led methadone maintenance service","volume":"105","author":"Oliver","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.10.005_bb0125","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1360-0443.2004.00707.x","article-title":"A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence","volume":"99","author":"Rawson","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.10.005_bb0130","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.addbeh.2013.03.018","article-title":"Duration effects in contingency management treatment of methamphetamine disorders","volume":"38","author":"Roll","year":"2013","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.jsat.2019.10.005_bb0135","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1176\/ajp.2006.163.11.1993","article-title":"Contingency management for the treatment of methamphetamine use disorders","volume":"163","author":"Roll","year":"2006","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.jsat.2019.10.005_bb0140","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/JCP.0000000000000408","article-title":"The effect of buprenorphine on methamphetamine cravings","volume":"35","author":"Salehi","year":"2015","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.jsat.2019.10.005_bb0145","author":"SAMHSA"},{"key":"10.1016\/j.jsat.2019.10.005_bb0150","series-title":"SAS\/ACCESS\u00ae 9.4 Interface to ADABAS. Reference","author":"SAS Institute Inc","year":"2013"},{"key":"10.1016\/j.jsat.2019.10.005_bb0155","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jfda.2013.09.037","article-title":"Medication-assisted treatment for opioid addiction: Methadone and buprenorphine","volume":"21","author":"Saxon","year":"2013","journal-title":"Journal of Food and Drug Analysis"},{"key":"10.1016\/j.jsat.2019.10.005_bb0160","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.drugalcdep.2018.01.017","article-title":"Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial","volume":"186","author":"Schottenfeld","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2019.10.005_bb0165","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","article-title":"Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995\u20132009","volume":"103","author":"Schwartz","year":"2013","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.jsat.2019.10.005_bb0170","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jsat.2009.05.003","article-title":"Buprenorphine maintenance treatment in a primary care setting: Outcomes at 1\u202fyear","volume":"37","author":"Soeffing","year":"2009","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.10.005_bb0175","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1525-1497.2005.0228.x","article-title":"Buprenorphine retention in primary care","volume":"20","author":"Stein","year":"2005","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.jsat.2019.10.005_bb0180","author":"Substance Abuse and Mental Health Services Administration"},{"key":"10.1016\/j.jsat.2019.10.005_bb0185","unstructured":"Substance Abuse and Mental Health Services Administration, 2018b. Medications for opioid use disorder: For healthcare and addiction professionals, policymakers, patients, and families. https:\/\/store.samhsa.gov\/system\/files\/sma18-5063fulldoc.pdf. accessed on 2018>."},{"key":"10.1016\/j.jsat.2019.10.005_bb0190","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1001\/jamainternmed.2014.5416","article-title":"Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users","volume":"174","author":"Tsui","year":"2014","journal-title":"JAMA Internal Medicine"},{"key":"10.1016\/j.jsat.2019.10.005_bb0195","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","article-title":"Long-term retention in office based opioid treatment with buprenorphine","volume":"74","author":"Weinstein","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.10.005_bb0200","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000130418","article-title":"Effect of methadone treatment on incarceration rates among injection drug users","volume":"14","author":"Werb","year":"2008","journal-title":"European Addiction Research"},{"key":"10.1016\/j.jsat.2019.10.005_bb0205","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5694\/mja13.00153","article-title":"Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: The HITS-c study","volume":"201","author":"White","year":"2014","journal-title":"The Medical Journal of Australia"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547219302508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547219302508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:50:38Z","timestamp":1760039438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547219302508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":43,"alternative-id":["S0740547219302508"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2019.10.005","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2019.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}